Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy

European Journal of Cancer

Volumn 83, Issue , 2017, Pages 28-31

  Boisseau, W ^a   Touat, M ^a   Berzero, G ^a,b   Savatovsky, J ^c   Marabelle, A ^d   Touitou, V ^a   Ricard, D ^a,e,f   Malouf, G ^a   Psimaras, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF PAVIA   (Italy)

^c FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Military Hospital Percy   (France)

^f Service de Santé des Armées   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; GADOLINIUM; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; PAZOPANIB; PREDNISONE; SUNITINIB; MONOCLONAL ANTIBODY;

ADULT; ADVERSE DRUG REACTION; CANCER SURGERY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CONTRAST ENHANCEMENT; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; EYE EXAMINATION; EYE SWELLING; FEMALE; HUMAN; KIDNEY CARCINOMA; LETTER; LIMB PAIN; MENINGITIS; MENINGORADICULITIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PRIORITY JOURNAL; RADICULITIS; SCOTOMA; VISUAL FIELD; VISUAL IMPAIRMENT; CHEMICALLY INDUCED; COMPLICATION; DRUG SUBSTITUTION; KIDNEY TUMOR; METASTASIS; OPTIC NERVE DISEASE; PATHOLOGY; RADICULOPATHY; RENAL CELL CARCINOMA;

ADULT; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; DRUG SUBSTITUTION; FEMALE; HUMANS; IPILIMUMAB; KIDNEY NEOPLASMS; MENINGITIS; NEOPLASM METASTASIS; OPTIC NERVE DISEASES; RADICULOPATHY;

EID: 85022072510     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.05.036     Document Type: Letter

References (17)

1. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010 Aug 19), 711–723.
2. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015 Jul 2), 23–34.
3. Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:2 (2015 Jul 9), 123–135.
4. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:17 (2015 Oct 22), 1627–1639.
5. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:19 (2015 Nov 5), 1803–1813.
6. Tarhini, Ahmad, Immune-mediated adverse events associated with ipilimumab Ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica, 2013, 2013.
7. Quirk, Shannon K., Shure, Anna K., Agrawal, Devendra K., Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma. Transl Res 166:5 (November 1, 2015), 412–424.
8. Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27:4 (2016 Apr 1), 559–574.
9. Spain, L., Walls, G., Julve, M., O'Meara, K., Schmid, T., Kalaitzaki, E., et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol Off J Eur Soc Med Oncol 28:2 (February 1, 2017), 377–385.
10. Vallet, H., Gaillet, A., Weiss, N., Vanhaecke, C., Saheb, S., Touitou, V., et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol/ESMO 27:7 (July 2016), 1352–1353.
11. Yeh, Oliver L., Francis, Courtney E., Ipilimumab-associated bilateral optic neuropathy. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc 35:2 (June 2015), 144–147.
12. Brown, Michael P., Hissaria, Pravin, Hc Hsieh, Amy, Kneebone, Christopher, Vallat, Wilson, Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol 305 (April 15, 2017), 16–18.
13. de Maleissye, M.F., Nicolas, G., Saiag, P., Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 375:3 (July 21, 2016), 296–297.
14. Maur, M., Tomasello, C., Frassoldati, A., Dieci, M.V., Barbieri, E., Conte, P., Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 30:6 (2012 Feb 20), e76–e78.
15. Menzies, A.M., Johnson, D.B., Ramanujam, S., Atkinson, V.G., Wong, A.N.M., Park, J.J., et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol Off J Eur Soc Med Oncol 28:2 (February 1, 2017), 368–376.
16. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M., Chen, L., Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7:2 (2007 Feb), 95–106.
17. Amin, A., DePril, V., Hamid, O., Wolchock, J., Maio, M., Neyns, B., et al. Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. J Clin Oncol, 27, 2009, 15s (suppl; abstr 9037) http://meetinglibrary.asco.org/content/34254-65.